- Home
- DIAX vs PHAR Comparison
DIAX vs PHAR Comparison
Compare DIAX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIAX
- PHAR
- Stock Information
- Founded
- DIAX 2005
- PHAR 1988
- Country
- DIAX United States
- PHAR Netherlands
- Employees
- DIAX N/A
- PHAR N/A
- Industry
- DIAX Finance Companies
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- DIAX Finance
- PHAR Health Care
- Exchange
- DIAX Nasdaq
- PHAR Nasdaq
- Market Cap
- DIAX 552.4M
- PHAR 624.1M
- IPO Year
- DIAX N/A
- PHAR N/A
- Fundamental
- Price
- DIAX $15.25
- PHAR $8.86
- Analyst Decision
- DIAX
- PHAR Strong Buy
- Analyst Count
- DIAX 0
- PHAR 3
- Target Price
- DIAX N/A
- PHAR $27.00
- AVG Volume (30 Days)
- DIAX 96.6K
- PHAR 5.9K
- Earning Date
- DIAX 01-01-0001
- PHAR 03-13-2025
- Dividend Yield
- DIAX 7.93%
- PHAR N/A
- EPS Growth
- DIAX N/A
- PHAR N/A
- EPS
- DIAX N/A
- PHAR N/A
- Revenue
- DIAX N/A
- PHAR $285,745,000.00
- Revenue This Year
- DIAX N/A
- PHAR $20.08
- Revenue Next Year
- DIAX N/A
- PHAR $9.22
- P/E Ratio
- DIAX N/A
- PHAR N/A
- Revenue Growth
- DIAX N/A
- PHAR 30.64
- 52 Week Low
- DIAX $12.80
- PHAR $6.65
- 52 Week High
- DIAX $15.12
- PHAR $12.20
- Technical
- Relative Strength Index (RSI)
- DIAX 39.73
- PHAR 48.50
- Support Level
- DIAX $15.34
- PHAR $8.50
- Resistance Level
- DIAX $15.55
- PHAR $9.50
- Average True Range (ATR)
- DIAX 0.16
- PHAR 0.56
- MACD
- DIAX -0.04
- PHAR 0.03
- Stochastic Oscillator
- DIAX 5.77
- PHAR 58.71
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.